Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 16, 2009

Lonza to Manufacture Elusys’ Antianthrax mAb

  • Lonza signed an agreement with Elusys Therapeutics for the manufacture of Anthin™, Elusys’ late -stage mAb against inhaled anthrax. Under terms of the deal, Lonza will provide process development services and manufacture the product using its GS Gene Expression System™.

    Anthin is a humanized, deimmunized mAb that targets the protective antigen of B. anthracis and neutralizes the effects of anthrax toxins. The antibody is being developed for both the prevention and treatment of inhalation anthrax. Elusys has been awarded $34 million from the NIH and DOD for development of the antibody. The product has also been granted fast-track status and orphan drug designation by the FDA. 



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »